Bal Pharma

Bal Pharma OCF/Debt

The Operating Cash Flow to Debt Ratio of Bal Pharma (BALPHARMA.NS) as of Nov 3, 2026 is 9.07 %. In the previous year, Operating Cash Flow to Debt Ratio was 2.81 % — a change of 222.44% (higher).

OCF/Debt

9.07 %

YoY

222.44%

Last updated:

Operating Cash Flow to Debt Ratio of Bal Pharma is 2026 9.07 % . Operating Cash Flow to Debt Ratio of Bal Pharma was 2025 2.81 % . It decreases by 222.44% higher compared to the previous year.

The Bal Pharma OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
6.28 INR
Jan 1, 2020
19.18 INR
Jan 1, 2021
19.12 INR
Jan 1, 2022
25.98 INR
Jan 1, 2023
-1.39 INR
Jan 1, 2024
16.03 INR
Jan 1, 2025
2.81 INR
Jan 1, 2026
9.07 INR
The Bal Pharma OCF/Debt history
YEAROCF/DebtYoY
9.07 %+222.44%
2.81 %-82.45%
16.03 %-1,257.33%
-1.39 %-105.33%
25.98 %+35.85%
19.12 %-0.31%
19.18 %+205.41%
6.28 %-1,492.59%
-0.45 %-107.17%
6.29 %-127.65%
-22.76 %-173.25%
31.06 %+18.35%
26.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bal Pharma Stock analysis

What does Bal Pharma do? Bal Pharma Ltd. generates revenue through the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company specializes in bulk actives, prescription drugs, generics, and pharma intermediates, targeting therapeutic areas such as anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. Its product portfolio includes APIs like antihistamine, platelet inhibitor, anti-diabetic, and anti-inflammatory agents, alongside finished formulations in tablets, capsules, syrups, and ointments. Key brands such as ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP are marketed to healthcare providers and consumers in these therapeutic segments. The company sells its APIs to other pharmaceutical manufacturers for further processing into finished products, while its finished formulations are distributed to hospitals, pharmacies, and clinics. Brands like AYURFINE and MENOLEAP CAPSULES target specific patient groups, such as those requiring anti-inflammatory or menopause treatment, respectively. The natural medicine line, including AYURSULIN and PROLIFE, caters to consumers seeking alternative treatments in diabetes and reproductive health. Revenue is derived from both B2B sales of APIs and direct B2C or B2B2C sales of branded formulations across multiple therapeutic categories. Bal Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bal Pharma stock

Operating Cash Flow to Debt Ratio of Bal Pharma is 9.07 % in 2026.

Operating Cash Flow to Debt Ratio of Bal Pharma changed from 2.81 % to 9.07 %, representing a 222.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Bal Pharma since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Bal Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bal Pharma

All Key Metrics — Bal Pharma